Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, April 4th. The firm currently has a $1.50 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 2.74% from the company’s current price.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 29th.
Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The company had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $0.63 million. analysts predict that Capricor Therapeutics will post -0.42 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of CAPR. Wells Fargo & Company MN acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $107,000. Jane Street Group LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $190,000. Belpointe Asset Management LLC acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $249,000. Finally, Brown Advisory Inc. acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $1,796,000. Institutional investors own 8.78% of the company’s stock.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.